Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maurizio Fava

Showing results (61-70 of 799) with videos related to

Pageof 80
Sort By:
Journal of Psychiatric Research|May 31, 2015
Changes in cognitive symptoms after a buspirone-melatonin combination treatment for Major Depressive DisorderSteven D Targum, Pamela C Wedel, Maurizio Fava
Current Psychiatry Reports|November 12, 2003
S-adenosyl-methionine in depression: a comprehensive review of the literatureGeorge I Papakostas, Jonathan E Alpert, Maurizio Fava
The Journal of Clinical Psychiatry|September 9, 2011
Evidence for the use of l-methylfolate combined with antidepressants in MDDMaurizio Fava, Richard C Shelton, John M Zajecka
The Journal of Clinical Psychiatry|October 9, 2014
Depression: addressing partial response after first-line antidepressant treatmentMichael E Thase, Maurizio Fava, Andrew A Nierenberg
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|May 10, 2024
Modulating self-referential processing through meditation and psychedelics: is scientific investigation of self-transcendence clinically relevant?Matthew D Sacchet, Maurizio Fava, Eric L Garland
Molecular Psychiatry|November 16, 2018
Can electronic health records revive central nervous system clinical trials?Roy H Perlis, Maurizio Fava, Thomas H McCoy
CNS Neuroscience & Therapeutics|May 17, 2008
Redefining affective disorders: relevance for drug developmentSteven D Targum, Mark H Pollack, Maurizio Fava
Journal of Clinical Psychopharmacology|August 16, 2003
Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetineMaurizio Fava, Patrick J McGrath, Wang-Pui Sheu, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|November 2, 2019
Rising placebo response rates threaten the validity of antipsychotic meta-analysesSamuel Dotson, David Mischoulon, Hang Lee, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 22, 2015
A Novel Methodology to Estimate the Treatment Effect in Presence of Highly Variable Placebo ResponseRoberto Gomeni, Navin Goyal, Françoise Bressolle, et al.
Pageof 80

Showing results (61-70 of 799) with videos related to

Sort By:
Pageof 80
Journal of Psychiatric Research|May 31, 2015
Changes in cognitive symptoms after a buspirone-melatonin combination treatment for Major Depressive DisorderSteven D Targum, Pamela C Wedel, Maurizio Fava
Current Psychiatry Reports|November 12, 2003
S-adenosyl-methionine in depression: a comprehensive review of the literatureGeorge I Papakostas, Jonathan E Alpert, Maurizio Fava
The Journal of Clinical Psychiatry|September 9, 2011
Evidence for the use of l-methylfolate combined with antidepressants in MDDMaurizio Fava, Richard C Shelton, John M Zajecka
The Journal of Clinical Psychiatry|October 9, 2014
Depression: addressing partial response after first-line antidepressant treatmentMichael E Thase, Maurizio Fava, Andrew A Nierenberg
World Psychiatry : Official Journal of the World Psychiatric Association (WPA)|May 10, 2024
Modulating self-referential processing through meditation and psychedelics: is scientific investigation of self-transcendence clinically relevant?Matthew D Sacchet, Maurizio Fava, Eric L Garland
Molecular Psychiatry|November 16, 2018
Can electronic health records revive central nervous system clinical trials?Roy H Perlis, Maurizio Fava, Thomas H McCoy
CNS Neuroscience & Therapeutics|May 17, 2008
Redefining affective disorders: relevance for drug developmentSteven D Targum, Mark H Pollack, Maurizio Fava
Journal of Clinical Psychopharmacology|August 16, 2003
Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetineMaurizio Fava, Patrick J McGrath, Wang-Pui Sheu, et al.
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|November 2, 2019
Rising placebo response rates threaten the validity of antipsychotic meta-analysesSamuel Dotson, David Mischoulon, Hang Lee, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 22, 2015
A Novel Methodology to Estimate the Treatment Effect in Presence of Highly Variable Placebo ResponseRoberto Gomeni, Navin Goyal, Françoise Bressolle, et al.
Pageof 80